MAP3K8 antibody

Catalog No. ABIN265369

Product Details anti-MAP3K8 Antibody

Target: MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))

Reactivity: Human, Rat, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MAP3K8 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)

Specificity: This antibody detects endogenous levels of MAP3K8 / TPL-2 protein(region surrounding Pro284).

Cross-Reactivity (Details): Species reactivity (expected):Mouse and Rat.
Species reactivity (tested):Human.

Purification: Affinity Chromatography using epitope-specific immunogen

Application Details

Application Notes: ELISA: 1/40000approx. 1/60000. Western Blot: 1/500approx. 1/1000. Immunofluorescence: 1/50approx. 1/200. Immunohistochemistry: 1/50approx. 1/200.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH ~7.2, 0.05 % Sodium Azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for MAP3K8

Target: MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))

Alternative Name: MAP3K8 / TPL-2 (MAP3K8 Products)

Synonyms: MAP3K8 antibody, COT antibody, EST antibody, ESTF antibody, MEKK8 antibody, TPL2 antibody, Tpl-2 antibody, c-COT antibody, Cot antibody, Cot/Tpl2 antibody, Est antibody, Estf antibody, Tpl2 antibody, D17TPL2 antibody, mitogen-activated protein kinase kinase kinase 8 antibody, MAP3K8 antibody, map3k8 antibody, Map3k8 antibody

Background: The role of mitogen-activated protein kinases (MAPKs) in cell signaling pathways is well established. The rat gene Tpl-2, for tumor progression locus 2, and the human and mouse homologues c-Cot, for cancer osaka thyroid oncogene, encode a proto-oncogene serine/threonine protein kinase that was shown to play a role in the functional activation of the MAP kinase pathway. Overexpression of Cot induces MAP kinase activation in COS-1 and NIH/3T3 cells. Cot-mediated activation of MAP kinase is inhibited by both Ras N17, a dominant negative mutant of c-H-Ras, and Raf-1s621A, a dominant negative mutant of Raf-1, suggesting that Cot functions upstream of Ras and Raf-1.Other studies have shown that a kinase-negative, dominant negative mutant of Cot partially blocks Ras or Raf-1-induced MAP kinase activation, arguing that Cot functions downstream of Ras and Raf-1. To explain these contrasting findings, it has been suggested that Cot, Ras and Raf-1 may form a multimeric complex that phosphorylates MEK-1. Cot has also been shown to be implicated in T lymphocyte activation.Synonyms: COT, COT proto-oncogene serine/threonine-protein kinase, Cancer Osaka thyroid oncogene, ESTF, MAPK, Mitogen-activated protein kinase kinase kinase 8, Tumor progression locus 2, Tumor progression locus 2

Molecular Weight: approx. 53 kDa

Gene ID: 1326

NCBI Accession: NP_005195

UniProt: P41279

Pathways: PI3K-Akt Signaling, TCR Signaling